Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: implications for the mechanism of polymerase action.
A computer model of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) either alone, or complexed with a non-nucleoside inhibitor (NNI), was constructed using crystal coordinate data from a subset of the protein surrounding the binding pocket region. Molecular mechanics calculations were carried out on solvated wild-type RT and RT that contained modifications corresponding to resistance-engendering mutations. Results from the calculations revealed that the r.m.s. difference between 12 modified proteins and that of wild-type RT could be qualitatively correlated with the measured polymerase activity of the enzyme in the presence of these mutations. In addition, the level of activity was related to the measured distance between the primer grip and dNTP binding regions of the protein. These data suggest a direct correlation between RT structure and function. Complexes of RT-8-C1 TIBO and RT-alpha-APA were also minimized in models containing modifications corresponding to key drug-resistant mutants. The variant complexes all showed weaker binding than wild-type RT, while giving rise to similar, but critical changes in the protein. Therefore, the design of new inhibitors should center on obtaining stronger binding drugs to key drug-resistant RT variants.
Kroeger Smith
M B
MB
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, MD 21702, USA.
Michejda
C J
CJ
Hughes
S H
SH
Boyer
P L
PL
Janssen
P A
PA
Andries
K
K
Buckheit
R W
RW
Smith
R H
RH
D019380:Anti-HIV Agents / Q000494:pharmacology; D001665:Binding Sites; D003198:Computer Simulation; D004352:Drug Resistance, Microbial; D004791:Enzyme Inhibitors / Q000494:pharmacology; D054303:HIV Reverse Transcriptase / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D008958:Models, Molecular; D009154:Mutation; D013329:Structure-Activity Relationship
D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D054303:HIV Reverse Transcriptase